首页 > 最新文献

Current pharmaceutical design最新文献

英文 中文
Alendronate for Effective Treatment of Male Osteoporosis : An Insight. 阿仑膦酸钠有效治疗男性骨质疏松症:透视。
IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-05 DOI: 10.2174/0113816128310838240820065324
Hanan Al Lawati, Sara Al Busaidi, Thuraiya Al Rawahi, Abdullah Al Lawati, Ahmed Kifah, Srijit Das

Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males. Various drugs, such as nitrogen-containing phosphonates, RANK ligand inhibitors, parathormones, and alendronate, have been used for effective treatment of osteoporosis. Alendronate (alendronic acid), a nitrogen-containing bisphosphonate that inhibits bone resorption by osteoclasts, was synthesized during the 1970s. In the present review, we discuss the pharmacokinetics, mechanism of action, adverse effects, contraindications, and toxicity monitoring of alendronate. The drug may be effectively used for the treatment of male osteoporosis in order to increase bone mineral density and prevent fractures.

骨质疏松症是一个重大的全球性健康问题。老年人骨质疏松症发病率的增加给治疗带来了挑战,也给国家造成了经济负担。女性骨质疏松症更受重视,而男性骨质疏松症则亟待解决。含氮膦酸盐、RANK 配体抑制剂、副激素和阿仑膦酸钠等多种药物已被用于有效治疗骨质疏松症。阿仑膦酸盐(阿仑膦酸)是一种含氮双膦酸盐,可抑制破骨细胞的骨吸收,于 20 世纪 70 年代合成。在本综述中,我们讨论了阿仑膦酸钠的药代动力学、作用机制、不良反应、禁忌症和毒性监测。该药物可有效用于治疗男性骨质疏松症,以增加骨矿密度和预防骨折。
{"title":"Alendronate for Effective Treatment of Male Osteoporosis : An Insight.","authors":"Hanan Al Lawati, Sara Al Busaidi, Thuraiya Al Rawahi, Abdullah Al Lawati, Ahmed Kifah, Srijit Das","doi":"10.2174/0113816128310838240820065324","DOIUrl":"https://doi.org/10.2174/0113816128310838240820065324","url":null,"abstract":"<p><p>Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males. Various drugs, such as nitrogen-containing phosphonates, RANK ligand inhibitors, parathormones, and alendronate, have been used for effective treatment of osteoporosis. Alendronate (alendronic acid), a nitrogen-containing bisphosphonate that inhibits bone resorption by osteoclasts, was synthesized during the 1970s. In the present review, we discuss the pharmacokinetics, mechanism of action, adverse effects, contraindications, and toxicity monitoring of alendronate. The drug may be effectively used for the treatment of male osteoporosis in order to increase bone mineral density and prevent fractures.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing Nanoparticles to Overcome Antimicrobial Resistance: Promises and Challenges. 利用纳米粒子克服抗菌剂耐药性:前景与挑战。
IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-29 DOI: 10.2174/0113816128326718240809091654
Akash Mishra, Anupam Jyoti, Krishna Aayush, Juhi Saxena, Kanika Sharma

The rise of antimicrobial resistance (AMR) has become a serious global health issue that kills millions of people each year globally. AMR developed in bacteria is difficult to treat and poses a challenge to clinicians. Bacteria develop resistance through a variety of processes, including biofilm growth, targeted area alterations, and therapeutic drug alteration, prolonging the period they remain within cells, where antibiotics are useless at therapeutic levels. This rise in resistance is linked to increased illness and death, highlighting the urgent need for effective solutions to combat this growing challenge. Nanoparticles (NPs) offer unique solutions for fighting AMR bacteria. Being smaller in size with a high surface area, enhancing interaction with bacteria makes the NPs strong antibacterial agents against various infections. In this review, we have discussed the epidemiology and mechanism of AMR development. Furthermore, the role of nanoparticles as antibacterial agents, and their role in drug delivery has been addressed. Additionally, the potential, challenges, toxicity, and future prospects of nanoparticles as antibacterial agents against AMR pathogens have been discussed. The research work discussed in this review links with Sustainable Development Goal 3 (SDG-3), which aims to ensure disease-free lives and promote well-being for all ages.

抗菌药耐药性(AMR)的增加已成为一个严重的全球健康问题,每年导致全球数百万人死亡。细菌产生的 AMR 难以治疗,给临床医生带来了挑战。细菌通过各种过程产生耐药性,包括生物膜生长、靶区改变和治疗药物改变,从而延长了细菌在细胞内的存活时间,使抗生素在治疗水平上失去作用。抗药性的增加与疾病和死亡的增加有关,因此迫切需要有效的解决方案来应对这一日益严峻的挑战。纳米粒子(NPs)为抗击 AMR 细菌提供了独特的解决方案。纳米粒子体积小、比表面积大,能增强与细菌的相互作用,是抗击各种感染的强力抗菌剂。在这篇综述中,我们讨论了 AMR 的流行病学和发展机制。此外,还讨论了纳米粒子作为抗菌剂的作用及其在药物输送中的作用。此外,我们还讨论了纳米粒子作为抗菌剂对抗 AMR 病原体的潜力、挑战、毒性和未来前景。本综述中讨论的研究工作与可持续发展目标 3(SDG-3)相关联,该目标旨在确保无疾病生活并促进所有年龄段的人的福祉。
{"title":"Harnessing Nanoparticles to Overcome Antimicrobial Resistance: Promises and Challenges.","authors":"Akash Mishra, Anupam Jyoti, Krishna Aayush, Juhi Saxena, Kanika Sharma","doi":"10.2174/0113816128326718240809091654","DOIUrl":"https://doi.org/10.2174/0113816128326718240809091654","url":null,"abstract":"<p><p>The rise of antimicrobial resistance (AMR) has become a serious global health issue that kills millions of people each year globally. AMR developed in bacteria is difficult to treat and poses a challenge to clinicians. Bacteria develop resistance through a variety of processes, including biofilm growth, targeted area alterations, and therapeutic drug alteration, prolonging the period they remain within cells, where antibiotics are useless at therapeutic levels. This rise in resistance is linked to increased illness and death, highlighting the urgent need for effective solutions to combat this growing challenge. Nanoparticles (NPs) offer unique solutions for fighting AMR bacteria. Being smaller in size with a high surface area, enhancing interaction with bacteria makes the NPs strong antibacterial agents against various infections. In this review, we have discussed the epidemiology and mechanism of AMR development. Furthermore, the role of nanoparticles as antibacterial agents, and their role in drug delivery has been addressed. Additionally, the potential, challenges, toxicity, and future prospects of nanoparticles as antibacterial agents against AMR pathogens have been discussed. The research work discussed in this review links with Sustainable Development Goal 3 (SDG-3), which aims to ensure disease-free lives and promote well-being for all ages.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-silico Studies and Antioxidant and Neuroprotective Assessment of Microencapsulated Celecoxib against Scopolamine-induced Alzheimer's Disease. 微胶囊塞来昔布针对东莨菪碱诱发的阿尔茨海默病的分子内研究及抗氧化和神经保护评估
IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-28 DOI: 10.2174/0113816128298289240723103828
Rajendra Herur Vishnumurthy, M Gnana Ruba Priya, Prashant Tiwari, Viswas Raja Solomon

Background and objective: Alzheimer's Disease (AD) is an enervating and chronic progressive neurodegenerative disorder. Celecoxib (CXB) possesses efficacious antioxidants and has neuroprotective, anti- inflammatory, and immunomodulatory properties. However, the poor bioavailability of CXB limits its therapeutic utility. Thus, this study aimed to evaluate the microencapsulated celecoxib MCXB) for neuroprotection.

Methodology: CXB was screened by molecular docking study using AutoDock (version 5.2), and the following proteins, such as 4EY7, 2HM1, 2Z5X, and 1PBQ were selected for predicting its neuroprotective effect. Scopolamine 20 mg/kg/day for approximately 7 days was administered to albino rats. Pure CXB 100 mg/kg/- day and 200 mg/kg/day, and MCXB 100 mg/kg/day and 200 mg/kg/day were administered, respectively. Further, to assess the oxidative stress, the nitric oxide (NO), superoxide dismutase (SOD), catalase, and lipid peroxidation (LPO) were evaluated using chemical methods. The neurochemical biomarkers like AChE, glutamate, and dopamine were evaluated using the ELISA method. Further, the histopathology of brain cells was carried out to assess the neuro-regeneration and neurodegeneration of the neurons.

Results: There was a significant binding interaction of CXB (score -6.3, -6.5, -5.1, -9.1) and donepezil (score- 5.5, -7.6, -7.0, and -8.6) with AchE (4EY7), β-secretase (2HM1, monoamine oxidase (2Z5X), and glutamate (1PBQ), respectively. MCXB-treated rats (100 mg/kg/day, 200 mg/kg/day) showed increased SOD levels (p < 0.001), whereas NO, catalase, and LPO levels were significantly (p < 0.001) decreased as compared to scopolamine-treated rats. Further, MCXB-treated rats showed a modulatory effect in the level of dopamine and AchE. However, the glutamate level was significantly (p < 0.001) decreased.

Conclusion: In addition to that, histopathological examination of the hippocampus part showed remarkable improvement in brain cells. So, the findings of the results revealed that MCXB, in a dose-dependent manner, showed a neuroprotective effect against scopolamine-induced AD. This effect may be attributed to the activation of cholinergic pathways.

背景和目的:阿尔茨海默氏症(AD)是一种慢性进行性神经退行性疾病。塞来昔布(CXB)是一种有效的抗氧化剂,具有神经保护、抗炎和免疫调节特性。然而,塞来昔布的生物利用度较低,限制了其治疗作用。因此,本研究旨在评估微囊塞来昔布(MCXB)的神经保护作用:使用 AutoDock(5.2 版)进行分子对接研究,筛选出 4EY7、2HM1、2Z5X 和 1PBQ 等蛋白质用于预测 CXB 的神经保护作用。给白化大鼠注射东莨菪碱 20 毫克/千克/天,持续约 7 天。分别给予纯 CXB 100 毫克/千克/天和 200 毫克/千克/天,以及 MCXB 100 毫克/千克/天和 200 毫克/千克/天。此外,为了评估氧化应激,还使用化学方法评估了一氧化氮(NO)、超氧化物歧化酶(SOD)、过氧化氢酶和脂质过氧化物(LPO)。使用 ELISA 方法评估了 AChE、谷氨酸和多巴胺等神经化学生物标志物。此外,还对脑细胞进行了组织病理学检查,以评估神经元的神经再生和神经退化情况:结果:CXB(得分-6.3、-6.5、-5.1、-9.1)和多奈哌齐(得分-5.5、-7.6、-7.0、-8.6)分别与 AchE(4EY7)、β-分泌酶(2HM1)、单胺氧化酶(2Z5X)和谷氨酸(1PBQ)有明显的结合相互作用。与东莨菪碱处理的大鼠相比,MCXB(100 毫克/千克/天、200 毫克/千克/天)处理的大鼠的 SOD 水平升高(p < 0.001),而 NO、过氧化氢酶和 LPO 水平则显著降低(p < 0.001)。此外,经 MCXB 处理的大鼠对多巴胺和 AchE 水平有调节作用。结论:MCXB 对大鼠的组织病理学研究结果表明,MCXB 对大鼠的多巴胺和 AchE 水平有调节作用,但谷氨酸水平明显下降(p < 0.001):此外,海马部分的组织病理学检查显示脑细胞有明显改善。因此,研究结果表明,MCXB 对东莨菪碱诱导的注意力缺失症具有神经保护作用。这种效应可能归因于胆碱能通路的激活。
{"title":"In-silico Studies and Antioxidant and Neuroprotective Assessment of Microencapsulated Celecoxib against Scopolamine-induced Alzheimer's Disease.","authors":"Rajendra Herur Vishnumurthy, M Gnana Ruba Priya, Prashant Tiwari, Viswas Raja Solomon","doi":"10.2174/0113816128298289240723103828","DOIUrl":"https://doi.org/10.2174/0113816128298289240723103828","url":null,"abstract":"<p><strong>Background and objective: </strong>Alzheimer's Disease (AD) is an enervating and chronic progressive neurodegenerative disorder. Celecoxib (CXB) possesses efficacious antioxidants and has neuroprotective, anti- inflammatory, and immunomodulatory properties. However, the poor bioavailability of CXB limits its therapeutic utility. Thus, this study aimed to evaluate the microencapsulated celecoxib MCXB) for neuroprotection.</p><p><strong>Methodology: </strong>CXB was screened by molecular docking study using AutoDock (version 5.2), and the following proteins, such as 4EY7, 2HM1, 2Z5X, and 1PBQ were selected for predicting its neuroprotective effect. Scopolamine 20 mg/kg/day for approximately 7 days was administered to albino rats. Pure CXB 100 mg/kg/- day and 200 mg/kg/day, and MCXB 100 mg/kg/day and 200 mg/kg/day were administered, respectively. Further, to assess the oxidative stress, the nitric oxide (NO), superoxide dismutase (SOD), catalase, and lipid peroxidation (LPO) were evaluated using chemical methods. The neurochemical biomarkers like AChE, glutamate, and dopamine were evaluated using the ELISA method. Further, the histopathology of brain cells was carried out to assess the neuro-regeneration and neurodegeneration of the neurons.</p><p><strong>Results: </strong>There was a significant binding interaction of CXB (score -6.3, -6.5, -5.1, -9.1) and donepezil (score- 5.5, -7.6, -7.0, and -8.6) with AchE (4EY7), β-secretase (2HM1, monoamine oxidase (2Z5X), and glutamate (1PBQ), respectively. MCXB-treated rats (100 mg/kg/day, 200 mg/kg/day) showed increased SOD levels (p < 0.001), whereas NO, catalase, and LPO levels were significantly (p < 0.001) decreased as compared to scopolamine-treated rats. Further, MCXB-treated rats showed a modulatory effect in the level of dopamine and AchE. However, the glutamate level was significantly (p < 0.001) decreased.</p><p><strong>Conclusion: </strong>In addition to that, histopathological examination of the hippocampus part showed remarkable improvement in brain cells. So, the findings of the results revealed that MCXB, in a dose-dependent manner, showed a neuroprotective effect against scopolamine-induced AD. This effect may be attributed to the activation of cholinergic pathways.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Murraya koenigii (L.) Spreng. as a Natural Intervention for Diabesity: A Review Murraya koenigii (L.) Spreng.作为治疗肥胖症的自然干预措施:综述
IF 3.1 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-28 DOI: 10.2174/0113816128304471240801183021
Sanjay Madhukar Jachak, Mridula Singh Thakur, Pallavi Ahirrao, Alok Goyal
Background: Murraya koenigii (L.) Spreng. (family: Rutaceae), commonly known as curry leaf or sweet neem, is a tropical plant native to India and Southeast Asia. It is highly valued in Ayurveda for its medicinal properties. Almost every part (fresh leaves, fruits, bark, and roots) of this plant is used to treat various ailments. Its fresh leaves are considered to have numerous medicinal properties for various diseases, including piles, inflammation, itching, fresh cuts, dysentery, and edema. A combination of curry leaf and buttermilk is used to treat diseases, such as amoebiasis, diabetes, and hepatitis. Its leaves are also believed to possess antioxidant, anti-inflammatory, and antimicrobial properties. The bark has been traditionally used for treating snakebites. Its roots are utilized in Ayurveda for the treatment of body aches. Being a storehouse of carbazole alkaloids, M. koenigii has been reported to show anti-obesity and anti-diabetic activity in in vitro and in vivo studies. The review aimed to appraise the role of M. koenigii leaf in the prevention of diabesity. Methods: We performed a literature search with the keywords “diabesity”, “obesity”, “diabetes”, “adipose tissue”, and “carbazole alkaloids” on Google Scholar, PubMed, and ScienceDirect databases. Several in vitro and in vivo studies conducted on cell lines and animals for anti-diabetic/anti-hyperglycemic and antihyperlipidemic activities have been included and appraised in the article, providing supporting evidence for the ethnomedicinal claims. Results and Conclusion: This review has been an attempt to summarize comprehensively the overall research done on M. koenigii with regard to obesity and diabetes. The studies on anti-diabetic/anti-hyperglycemic and anti-hyperlipidemic activities of the plant have ranged from studies on crude extracts to isolated compounds. However, some of the studies require further in-depth analysis and validation of obtained results.
背景介绍Murraya koenigii (L.) Spreng.(芸香科),俗称咖喱叶或甜楝树,是一种原产于印度和东南亚的热带植物。在阿育吠陀中,它的药用价值很高。这种植物的几乎每个部分(鲜叶、果实、树皮和根)都可用于治疗各种疾病。它的鲜叶被认为对痔疮、炎症、瘙痒、新伤口、痢疾和水肿等各种疾病具有多种药用功效。咖喱叶与酪乳的组合可用于治疗阿米巴病、糖尿病和肝炎等疾病。人们还认为咖喱叶具有抗氧化、消炎和抗菌的功效。树皮传统上用于治疗蛇咬伤。其根部在阿育吠陀中用于治疗身体疼痛。据报道,作为咔唑生物碱的宝库,M. koenigii 在体外和体内研究中显示出抗肥胖和抗糖尿病活性。本综述旨在评估鹅掌楸叶在预防肥胖症方面的作用。方法:我们在 Google Scholar、PubMed 和 ScienceDirect 数据库中以 "肥胖症"、"肥胖"、"糖尿病"、"脂肪组织 "和 "咔唑生物碱 "为关键词进行了文献检索。文章纳入并评估了在细胞系和动物身上进行的几项抗糖尿病/抗高血糖和抗高血脂活性的体外和体内研究,为民族药用声称提供了佐证。结果与结论:本综述试图全面总结有关柯尼希菌在肥胖症和糖尿病方面的整体研究。有关该植物抗糖尿病/抗高血糖和抗高血脂活性的研究包括粗提取物研究和分离化合物研究。然而,其中一些研究还需要进一步深入分析和验证所获得的结果。
{"title":"Murraya koenigii (L.) Spreng. as a Natural Intervention for Diabesity: A Review","authors":"Sanjay Madhukar Jachak, Mridula Singh Thakur, Pallavi Ahirrao, Alok Goyal","doi":"10.2174/0113816128304471240801183021","DOIUrl":"https://doi.org/10.2174/0113816128304471240801183021","url":null,"abstract":"Background: Murraya koenigii (L.) Spreng. (family: Rutaceae), commonly known as curry leaf or sweet neem, is a tropical plant native to India and Southeast Asia. It is highly valued in Ayurveda for its medicinal properties. Almost every part (fresh leaves, fruits, bark, and roots) of this plant is used to treat various ailments. Its fresh leaves are considered to have numerous medicinal properties for various diseases, including piles, inflammation, itching, fresh cuts, dysentery, and edema. A combination of curry leaf and buttermilk is used to treat diseases, such as amoebiasis, diabetes, and hepatitis. Its leaves are also believed to possess antioxidant, anti-inflammatory, and antimicrobial properties. The bark has been traditionally used for treating snakebites. Its roots are utilized in Ayurveda for the treatment of body aches. Being a storehouse of carbazole alkaloids, M. koenigii has been reported to show anti-obesity and anti-diabetic activity in in vitro and in vivo studies. The review aimed to appraise the role of M. koenigii leaf in the prevention of diabesity. Methods: We performed a literature search with the keywords “diabesity”, “obesity”, “diabetes”, “adipose tissue”, and “carbazole alkaloids” on Google Scholar, PubMed, and ScienceDirect databases. Several in vitro and in vivo studies conducted on cell lines and animals for anti-diabetic/anti-hyperglycemic and antihyperlipidemic activities have been included and appraised in the article, providing supporting evidence for the ethnomedicinal claims. Results and Conclusion: This review has been an attempt to summarize comprehensively the overall research done on M. koenigii with regard to obesity and diabetes. The studies on anti-diabetic/anti-hyperglycemic and anti-hyperlipidemic activities of the plant have ranged from studies on crude extracts to isolated compounds. However, some of the studies require further in-depth analysis and validation of obtained results.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":"402 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142202709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Activin A-Targeted Therapy in Cancer: An Updated Review on Challenges and Opportunities in Clinical Translation 癌症中的激活素 A 靶向疗法:关于临床转化的挑战与机遇的最新综述
IF 3.1 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-28 DOI: 10.2174/0113816128320120240805104433
Nima Rastegar-Pouyani, Mohammad Amin Farzin, Pegah Karimi, Sedighe Kolivand, Emad Jafarzadeh, Mohadeseh Haji Abdolvahab, Masoud Najafi
Activin A (ActA) is a cytokine from the TGF-β superfamily that mediates a vast number of physiological mechanisms, mainly through the SMAD signaling pathway. Growing evidence indicates that ActA overexpression is also correlated with poor prognosis in cancer patients and several tumor characteristics, including cancer proliferation, metastasis, immunosuppression, drug resistance, cachexia, and cancer-associated fibroblast activation. As such, ActA-targeted therapy has been viewed as a potential adjuvant therapy alongside other anti-cancer modalities that may result in more efficient anti-cancer effects, such as stronger immune responses, overcoming drug resistance, reversing cachexia, etc. However, despite its interesting concept, targeting ActA is not without certain challenges and considerations. Indeed, ActA has unexpectedly shown anti-tumor effects in some cases, which might be explained by differences in the expression levels of different ActA receptors on the cell surface, activation of non-SMAD pathways, and imbalance in ActA levels. Besides, many of the current ActA antagonists lack enough specificity and, as a result, bind to non-ActA receptors as well. Furthermore, ubiquitous expression of ActA in the body can cause serious adverse effects following systemic administration. Furthermore, to address these issues, anti-ActA monoclonal antibodies and nanoparticle drug delivery systems have recently been suggested to target ActA with better precision in the affected area. In this review, first, we provide the different implications of ActA in cancer. Then, we discuss the recent insights into targeting ActA signaling as an adjuvant therapy alongside other anti-cancer modalities, as well as the possible challenges and novel opportunities on the path of clinical translation.
激活素 A(ActA)是 TGF-β 超家族中的一种细胞因子,主要通过 SMAD 信号通路介导大量生理机制。越来越多的证据表明,ActA 的过表达与癌症患者的不良预后以及癌症增殖、转移、免疫抑制、耐药性、恶病质和癌症相关成纤维细胞激活等多种肿瘤特征相关。因此,ActA 靶向疗法被视为一种潜在的辅助疗法,可与其他抗癌方式一起产生更有效的抗癌效果,如更强的免疫反应、克服耐药性、逆转恶病质等。然而,尽管其概念很有趣,但以 ActA 为靶点并非没有一定的挑战和考虑因素。事实上,ActA 在某些情况下会意外地显示出抗肿瘤效果,这可能是由于细胞表面不同 ActA 受体的表达水平存在差异、非 SMAD 通路被激活以及 ActA 水平失衡等原因造成的。此外,目前许多 ActA 拮抗剂缺乏足够的特异性,因此也会与非 ActA 受体结合。此外,ActA 在体内的普遍表达会在全身用药后产生严重的不良反应。此外,为了解决这些问题,最近有人提出了抗ActA单克隆抗体和纳米颗粒给药系统,以更精确地靶向ActA受累区域。在这篇综述中,我们首先介绍了 ActA 对癌症的不同影响。然后,我们将讨论针对 ActA 信号与其他抗癌方法一起作为辅助疗法的最新见解,以及在临床转化道路上可能面临的挑战和新机遇。
{"title":"Activin A-Targeted Therapy in Cancer: An Updated Review on Challenges and Opportunities in Clinical Translation","authors":"Nima Rastegar-Pouyani, Mohammad Amin Farzin, Pegah Karimi, Sedighe Kolivand, Emad Jafarzadeh, Mohadeseh Haji Abdolvahab, Masoud Najafi","doi":"10.2174/0113816128320120240805104433","DOIUrl":"https://doi.org/10.2174/0113816128320120240805104433","url":null,"abstract":"Activin A (ActA) is a cytokine from the TGF-β superfamily that mediates a vast number of physiological mechanisms, mainly through the SMAD signaling pathway. Growing evidence indicates that ActA overexpression is also correlated with poor prognosis in cancer patients and several tumor characteristics, including cancer proliferation, metastasis, immunosuppression, drug resistance, cachexia, and cancer-associated fibroblast activation. As such, ActA-targeted therapy has been viewed as a potential adjuvant therapy alongside other anti-cancer modalities that may result in more efficient anti-cancer effects, such as stronger immune responses, overcoming drug resistance, reversing cachexia, etc. However, despite its interesting concept, targeting ActA is not without certain challenges and considerations. Indeed, ActA has unexpectedly shown anti-tumor effects in some cases, which might be explained by differences in the expression levels of different ActA receptors on the cell surface, activation of non-SMAD pathways, and imbalance in ActA levels. Besides, many of the current ActA antagonists lack enough specificity and, as a result, bind to non-ActA receptors as well. Furthermore, ubiquitous expression of ActA in the body can cause serious adverse effects following systemic administration. Furthermore, to address these issues, anti-ActA monoclonal antibodies and nanoparticle drug delivery systems have recently been suggested to target ActA with better precision in the affected area. In this review, first, we provide the different implications of ActA in cancer. Then, we discuss the recent insights into targeting ActA signaling as an adjuvant therapy alongside other anti-cancer modalities, as well as the possible challenges and novel opportunities on the path of clinical translation.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":"53 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142202721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnesium (Mg2+): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation 镁(Mg2+):神经元健康的必需矿物质:从细胞生物化学到认知健康和行为调节
IF 3.1 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-27 DOI: 10.2174/0113816128321466240816075041
Aakash Kumar, Sidharth Mehan, Aarti Tiwari, Zuber Khan, Ghanshyam Das Gupta, Acharan S. Narula, Rajaram Samant
Magnesium (Mg2+) is a crucial mineral involved in numerous cellular processes critical for neuronal health and function. This review explores the multifaceted roles of Mg2+, from its biochemical interactions at the cellular level to its impact on cognitive health and behavioral regulation. Mg2+ acts as a cofactor for over 300 enzymatic reactions, including those involved in ATP synthesis, nucleic acid stability, and neurotransmitter release. It regulates ion channels, modulates synaptic plasticity, and maintains the structural integrity of cell membranes, which are essential for proper neuronal signaling and synaptic transmission. Recent studies have highlighted the significance of Mg2+ in neuroprotection, showing its ability to attenuate oxidative stress, reduce inflammation, and mitigate excitotoxicity, thereby safeguarding neuronal health. Furthermore, Mg2+ deficiency has been linked to a range of neuropsychiatric disorders, including depression, anxiety, and cognitive decline. Supplementation with Mg2+, particularly in the form of bioavailable compounds such as Magnesium-L-Threonate (MgLT), Magnesium-Acetyl-Taurate (MgAT), and other Magnesium salts, has shown some promising results in enhancing synaptic density, improving memory function, and alleviating symptoms of mental health disorders. This review highlights significant current findings on the cellular mechanisms by which Mg2+ exerts its neuroprotective effects and evaluates clinical and preclinical evidence supporting its therapeutic potential. By elucidating the comprehensive role of Mg2+ in neuronal health, this review aims to underscore the importance of maintaining optimal Mg2+ levels for cognitive function and behavioral regulation, advocating for further research into Mg2+ supplementation as a viable intervention for neuropsychiatric and neurodegenerative conditions.
镁(Mg2+)是一种重要的矿物质,它参与了许多对神经元健康和功能至关重要的细胞过程。本综述探讨了 Mg2+ 的多方面作用,从其在细胞水平的生化相互作用到其对认知健康和行为调节的影响。Mg2+ 是 300 多种酶促反应的辅助因子,包括参与 ATP 合成、核酸稳定性和神经递质释放的反应。它还能调节离子通道、调节突触的可塑性,并保持细胞膜结构的完整性,这对神经元信号的正常传递和突触传输至关重要。最近的研究强调了 Mg2+ 在神经保护中的重要作用,表明它能够减轻氧化应激、减少炎症和减轻兴奋毒性,从而保护神经元的健康。此外,Mg2+ 缺乏还与一系列神经精神疾病有关,包括抑郁症、焦虑症和认知能力下降。补充 Mg2+,特别是以生物可利用化合物的形式补充 Mg2+,如柠檬酸镁(MgLT)、乙酰牛磺酸镁(MgAT)和其他镁盐,在增强突触密度、改善记忆功能和缓解精神疾病症状方面取得了一些有希望的结果。本综述重点介绍了目前关于 Mg2+ 发挥神经保护作用的细胞机制的重要发现,并评估了支持其治疗潜力的临床和临床前证据。通过阐明 Mg2+ 在神经元健康中的综合作用,本综述旨在强调维持最佳 Mg2+ 水平对认知功能和行为调节的重要性,倡导进一步研究 Mg2+ 补充剂,将其作为治疗神经精神疾病和神经退行性疾病的可行干预措施。
{"title":"Magnesium (Mg2+): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation","authors":"Aakash Kumar, Sidharth Mehan, Aarti Tiwari, Zuber Khan, Ghanshyam Das Gupta, Acharan S. Narula, Rajaram Samant","doi":"10.2174/0113816128321466240816075041","DOIUrl":"https://doi.org/10.2174/0113816128321466240816075041","url":null,"abstract":"Magnesium (Mg2+) is a crucial mineral involved in numerous cellular processes critical for neuronal health and function. This review explores the multifaceted roles of Mg2+, from its biochemical interactions at the cellular level to its impact on cognitive health and behavioral regulation. Mg2+ acts as a cofactor for over 300 enzymatic reactions, including those involved in ATP synthesis, nucleic acid stability, and neurotransmitter release. It regulates ion channels, modulates synaptic plasticity, and maintains the structural integrity of cell membranes, which are essential for proper neuronal signaling and synaptic transmission. Recent studies have highlighted the significance of Mg2+ in neuroprotection, showing its ability to attenuate oxidative stress, reduce inflammation, and mitigate excitotoxicity, thereby safeguarding neuronal health. Furthermore, Mg2+ deficiency has been linked to a range of neuropsychiatric disorders, including depression, anxiety, and cognitive decline. Supplementation with Mg2+, particularly in the form of bioavailable compounds such as Magnesium-L-Threonate (MgLT), Magnesium-Acetyl-Taurate (MgAT), and other Magnesium salts, has shown some promising results in enhancing synaptic density, improving memory function, and alleviating symptoms of mental health disorders. This review highlights significant current findings on the cellular mechanisms by which Mg2+ exerts its neuroprotective effects and evaluates clinical and preclinical evidence supporting its therapeutic potential. By elucidating the comprehensive role of Mg2+ in neuronal health, this review aims to underscore the importance of maintaining optimal Mg2+ levels for cognitive function and behavioral regulation, advocating for further research into Mg2+ supplementation as a viable intervention for neuropsychiatric and neurodegenerative conditions.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":"21 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142202710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Potential Inhibitors from Medicinal Plant-based Phytochemicals for the Influential C4 Target of Diabetic Retinopathy by Molecular Docking Studies. 通过分子对接研究从药用植物为基础的植物化学物质中鉴定糖尿病视网膜病变重要 C4 靶点的潜在抑制剂。
IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-08 DOI: 10.2174/0113816128297758240723104452
Veerachamy Alagarsamy, Mohaideen Thasthagir Sulthana, Viswas Raja Solomon, Aithamraju Satishchandra, Vishaka Sumant Kulkarni, Bandi Narendhar, Sankaranarayanan Murugesan, Mohammed Muzaffar-Ur-Rehman, Ala Chandu

Introduction: Diabetic retinopathy is the major cause of vision failure in diabetic patients, and the current treatment involves the practice of glucocorticoids or VEGF antagonists that are "off-label". A few small organic molecules against DR were discovered many years ago. Nutraceuticals are naturally available functional foods that endorse different health benefits, including vitamins, antioxidants, minerals, fatty acids, and amino acids that can defer the development of some diseases.

Methods: Numerous studies reported that nutraceuticals encourage multiple therapeutic benefits and provide protection against various diseases. In diabetes, nutraceuticals contribute to improving insulin sensitivity, metabolism regulation, and lower hyperglycemia. The major aim of this study is to discover the most active drug from natural or plant sources. In this work, 42 phytochemical constituents from 4 kinds of plants were docked with the C4 target of diabetic retinopathy by an in silico molecular docking study.

Results: According to the binding energy, all the phytoconstituents possessed good to high attraction towards the target, and 6 phytochemicals, such as terchebulin, punicalagin, chebulagic acid, casuarinin, punicalin, and pedunculagin, disclosed superior binding energy towards the target than standard ruboxistaurin via the interactions of conventional hydrogen bonding, pi-alkyl interactions, etc. Molecular dynamic simulation studies further established the stability of the phytoconstituents, and ADMET studies proved the safety profile of these phytoconstituents.

Conclusion: Hence, the current study suggested that the phytochemicals from various herbs inhibit the C4 target of diabetic retinopathy and can be utilized as lead compounds to develop analogs or repurposed for the treatment of DR.

简介:糖尿病视网膜病变是糖尿病患者视力衰退的主要原因:糖尿病视网膜病变是糖尿病患者视力衰退的主要原因,目前的治疗方法包括使用糖皮质激素或血管内皮生长因子拮抗剂等 "标签外 "药物。多年前,人们发现了一些抗 DR 的有机小分子。营养保健品是天然的功能性食品,具有不同的健康益处,包括维生素、抗氧化剂、矿物质、脂肪酸和氨基酸,可延缓某些疾病的发展:大量研究报告表明,营养保健食品具有多种治疗功效,可预防各种疾病。对于糖尿病患者来说,营养保健品有助于改善胰岛素敏感性、调节新陈代谢和降低高血糖。这项研究的主要目的是从天然或植物资源中发现最具活性的药物。本研究通过硅学分子对接研究,将 4 种植物中的 42 种植物化学成分与糖尿病视网膜病变的 C4 靶点进行了对接:结果表明:从结合能来看,所有植物化学成分对靶点均具有良好至较高的吸引力,其中6种植物化学成分,如槲皮素、番泻叶苷、诃子酸、槲皮素、番泻叶苷和山梗菜苷,通过常规的氢键、烷基相互作用等,对靶点的结合能优于标准的红没药苷。分子动态模拟研究进一步证实了这些植物成分的稳定性,而 ADMET 研究则证明了这些植物成分的安全性:因此,目前的研究表明,各种草药中的植物化学物质能抑制糖尿病视网膜病变的 C4 靶点,可作为先导化合物开发类似物或重新用于治疗糖尿病视网膜病变。
{"title":"Identification of Potential Inhibitors from Medicinal Plant-based Phytochemicals for the Influential C4 Target of Diabetic Retinopathy by Molecular Docking Studies.","authors":"Veerachamy Alagarsamy, Mohaideen Thasthagir Sulthana, Viswas Raja Solomon, Aithamraju Satishchandra, Vishaka Sumant Kulkarni, Bandi Narendhar, Sankaranarayanan Murugesan, Mohammed Muzaffar-Ur-Rehman, Ala Chandu","doi":"10.2174/0113816128297758240723104452","DOIUrl":"https://doi.org/10.2174/0113816128297758240723104452","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic retinopathy is the major cause of vision failure in diabetic patients, and the current treatment involves the practice of glucocorticoids or VEGF antagonists that are \"off-label\". A few small organic molecules against DR were discovered many years ago. Nutraceuticals are naturally available functional foods that endorse different health benefits, including vitamins, antioxidants, minerals, fatty acids, and amino acids that can defer the development of some diseases.</p><p><strong>Methods: </strong>Numerous studies reported that nutraceuticals encourage multiple therapeutic benefits and provide protection against various diseases. In diabetes, nutraceuticals contribute to improving insulin sensitivity, metabolism regulation, and lower hyperglycemia. The major aim of this study is to discover the most active drug from natural or plant sources. In this work, 42 phytochemical constituents from 4 kinds of plants were docked with the C4 target of diabetic retinopathy by an in silico molecular docking study.</p><p><strong>Results: </strong>According to the binding energy, all the phytoconstituents possessed good to high attraction towards the target, and 6 phytochemicals, such as terchebulin, punicalagin, chebulagic acid, casuarinin, punicalin, and pedunculagin, disclosed superior binding energy towards the target than standard ruboxistaurin via the interactions of conventional hydrogen bonding, pi-alkyl interactions, etc. Molecular dynamic simulation studies further established the stability of the phytoconstituents, and ADMET studies proved the safety profile of these phytoconstituents.</p><p><strong>Conclusion: </strong>Hence, the current study suggested that the phytochemicals from various herbs inhibit the C4 target of diabetic retinopathy and can be utilized as lead compounds to develop analogs or repurposed for the treatment of DR.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of De Quervain disease in infant caregivers and its association with risk factors. 婴幼儿护理人员中德-夸父病的发病率及其与风险因素的关联。
IF 0.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 DOI: 10.47391/JPMA.4916
Aneeqa Manzoor, Sidra Syed, Mishal Nadeem, Sara Khawar Butt, Syeda Nabiha Zafar, Muhammad Kamran Hanif

De Quervain's disease (DQD) is commonly reported in mothers during pregnancy up to delayed postpartum period. A cross-sectional study was conducted to assess infant caregivers who visited the paediatric outpatient department or vaccination centre in two hospitals of Lahore, during the months of May and June, 2021. A total of 190 subjects were interviewed directly and assessed by applying Finkelstein's test on both hands. Data was collected using Numeric Pain Rating Scale (NPRS) and Patient Rated Wrist Evaluation (PRWE) from positive subjects. They were asked to report their pain and difficulty level of the affected hand with worsened symptoms. The results exhibited 26.8% prevalence of DQD in a sample size of 190. Infant's age, lifting frequency and hand dominance were proved significant risk factors. However, caregiver's age, history of wrist pain, infant weight and relationship with infant were proved insignificant. Mean PRWE pain and functional scores were 23.14±7.72 and 18.53±6.09, respectively.

据报道,母亲在怀孕期间至产后延迟期经常会患上德-克万氏病(DQD)。我们开展了一项横断面研究,对 2021 年 5 月和 6 月期间前往拉合尔两家医院儿科门诊部或疫苗接种中心就诊的婴儿看护者进行了评估。共有 190 名受试者接受了直接访谈,并通过对双手进行芬克尔斯坦测试进行了评估。对阳性受试者使用数字疼痛评分量表(NPRS)和患者腕部评价(PRWE)收集数据。他们被要求报告患手的疼痛和困难程度,以及症状恶化的情况。结果显示,在 190 个样本中,DQD 患病率为 26.8%。婴儿的年龄、提举频率和手的优势被证明是重要的风险因素。然而,护理人员的年龄、腕痛病史、婴儿体重以及与婴儿的关系被证明并不重要。PRWE疼痛和功能评分的平均值分别为(23.14±7.72)分和(18.53±6.09)分。
{"title":"Prevalence of De Quervain disease in infant caregivers and its association with risk factors.","authors":"Aneeqa Manzoor, Sidra Syed, Mishal Nadeem, Sara Khawar Butt, Syeda Nabiha Zafar, Muhammad Kamran Hanif","doi":"10.47391/JPMA.4916","DOIUrl":"10.47391/JPMA.4916","url":null,"abstract":"<p><p>De Quervain's disease (DQD) is commonly reported in mothers during pregnancy up to delayed postpartum period. A cross-sectional study was conducted to assess infant caregivers who visited the paediatric outpatient department or vaccination centre in two hospitals of Lahore, during the months of May and June, 2021. A total of 190 subjects were interviewed directly and assessed by applying Finkelstein's test on both hands. Data was collected using Numeric Pain Rating Scale (NPRS) and Patient Rated Wrist Evaluation (PRWE) from positive subjects. They were asked to report their pain and difficulty level of the affected hand with worsened symptoms. The results exhibited 26.8% prevalence of DQD in a sample size of 190. Infant's age, lifting frequency and hand dominance were proved significant risk factors. However, caregiver's age, history of wrist pain, infant weight and relationship with infant were proved insignificant. Mean PRWE pain and functional scores were 23.14±7.72 and 18.53±6.09, respectively.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":"19 29 1","pages":"1335-1337"},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90316485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-surgical Synergistic Interventions for the Treatment of Skin Cancer. 治疗皮肤癌的非手术协同干预。
IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-20 DOI: 10.2174/0113816128298264240530061039
Magdi Abobaker, Mershen Govender, Yahya E Choonara

Skin cancer is broadly classified into two categories i.e., non-melanoma skin cancer (NMSC) and malignant melanoma (MM), with MM having a greater fatality rate than NMSC. A large number of treatment strategies currently exist for these skin cancer types, ranging from monotherapies to complex multifaceted synergistic interventions including dual therapies, trimodality therapy, and multicomponent combinations therapy. These combinatorial cancer treatments have delivered more favorable results when compared with monotherapies, and although combination treatments increase the cost of treatment, these regimens have lower side effect profiles, decreased resistance, high efficacy and an improved long-term response. Synergistic combination treatments for skin cancer are often complex, wide-ranging and encompass diverse platforms with various mechanisms of action. An understanding of the physiological potential, as well the efficacy of such treatments, is therefore vital to ensure patients receive the best possible treatment. This review therefore focuses on the current advancements and existing non-surgical combinative drug delivery methods utilized for treating skin cancer. It encompasses the diverse pharmaceutical delivery systems, clinical outcomes, and oncology strategies employed and aims to highlight the role of non-surgical combination therapies in enhancing patient compliance, reducing treatment durations, and improving overall survival rates while addressing relapses and metastasis. The promising outlook of the research being conducted in this field has also been provided, as well as the barriers to the effective treatment of this complex condition.

皮肤癌大致分为两类,即非黑色素瘤皮肤癌(NMSC)和恶性黑色素瘤(MM),其中恶性黑色素瘤的致死率高于非黑色素瘤皮肤癌。针对这些皮肤癌类型,目前存在大量治疗策略,从单一疗法到复杂的多方面协同干预,包括双重疗法、三模疗法和多成分组合疗法。与单一疗法相比,这些癌症综合疗法的疗效更佳,虽然综合疗法增加了治疗成本,但这些疗法的副作用较低,耐药性减少,疗效高,长期反应也有所改善。皮肤癌的协同联合疗法通常复杂、广泛,包含具有各种作用机制的不同平台。因此,了解此类疗法的生理潜力和疗效对于确保患者获得最佳治疗至关重要。因此,本综述将重点介绍目前用于治疗皮肤癌的先进技术和现有的非手术联合给药方法。它包括所采用的各种给药系统、临床结果和肿瘤学策略,旨在强调非手术综合疗法在提高患者依从性、缩短治疗时间、提高总体生存率以及解决复发和转移问题方面的作用。此外,还介绍了这一领域的研究前景,以及有效治疗这一复杂疾病的障碍。
{"title":"Non-surgical Synergistic Interventions for the Treatment of Skin Cancer.","authors":"Magdi Abobaker, Mershen Govender, Yahya E Choonara","doi":"10.2174/0113816128298264240530061039","DOIUrl":"https://doi.org/10.2174/0113816128298264240530061039","url":null,"abstract":"<p><p>Skin cancer is broadly classified into two categories i.e., non-melanoma skin cancer (NMSC) and malignant melanoma (MM), with MM having a greater fatality rate than NMSC. A large number of treatment strategies currently exist for these skin cancer types, ranging from monotherapies to complex multifaceted synergistic interventions including dual therapies, trimodality therapy, and multicomponent combinations therapy. These combinatorial cancer treatments have delivered more favorable results when compared with monotherapies, and although combination treatments increase the cost of treatment, these regimens have lower side effect profiles, decreased resistance, high efficacy and an improved long-term response. Synergistic combination treatments for skin cancer are often complex, wide-ranging and encompass diverse platforms with various mechanisms of action. An understanding of the physiological potential, as well the efficacy of such treatments, is therefore vital to ensure patients receive the best possible treatment. This review therefore focuses on the current advancements and existing non-surgical combinative drug delivery methods utilized for treating skin cancer. It encompasses the diverse pharmaceutical delivery systems, clinical outcomes, and oncology strategies employed and aims to highlight the role of non-surgical combination therapies in enhancing patient compliance, reducing treatment durations, and improving overall survival rates while addressing relapses and metastasis. The promising outlook of the research being conducted in this field has also been provided, as well as the barriers to the effective treatment of this complex condition.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Integrative Network Pharmacology and Bioinformatics Approach for Deciphering the Multi-target Effect of Nyctanthes arbortristis L. against COVID-19. 用网络药理学和生物信息学综合方法破解 Nyctanthes arbortristis L. 对 COVID-19 的多靶点效应
IF 3.1 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-11 DOI: 10.2174/0113816128298950240428013723
Nagaraja Sreeharsha, Girish Meravanige Basavarajappa, Bandar Aloufi, Predeepkumar Narayanappa Shiroorkar, Md Khalid Anwer, Abdur Rehman

Introduction: The COVID-19 pandemic represents a significant challenge across scientific, medical, and societal dimensions. The unpredictability of the disease progression, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), underscores the urgent need for identifying compounds that target multiple aspects of the virus to ensure swift and effective treatment. Nyctanthes arbortristis L., a delicate, perennial, deciduous shrub found across various Asian regions, has been recognized for its wide range of pharmacological benefits, including hepatoprotective, antimalarial, antibacterial, anti-inflammatory, antioxidant, and antiviral properties.

Methods: Various in vitro studies revealed the therapeutic significance of Nyctanthes arbortristis against COVID-19. However, the exact molecular mechanism remains unclarified. In the present study, a network pharmacology approach was employed to uncover the active ingredients, their potential targets, and signaling pathways in Nyctanthes arbortristis for the treatment of COVID-19. In the framework of this study, we explored the active ingredient-target-pathway network and figured out that naringetol, ursolic acid, betasitosterol, and daucosterol decisively contributed to the development of COVID-19 by affecting IL6, MAPK3, and MDM2 genes.

Results: The results of molecular docking analysis indicated that Nyctanthes arbortristis exerted effective binding capacity in COVID-19. Further, we disclosed the targets, biological functions, and signaling pathways of Nyctanthes arbortristis in COVID-19. The analysis indicated that Nyctanthes arbortristis could help treat COVID-19 through the enhancement of immunologic functions, inhibition of inflammatory reactions and regulation of the cellular microenvironment. In short, the current study used a series of network pharmacologybased and computational analyses to understand and characterize the binding capacity, biological functions, pharmacological targets and therapeutic mechanisms of Nyctanthes arbortristis in COVID-19.

Conclusion: However, the findings were not validated in actual COVID-19 patients, so further investigation is needed to confirm the potential use of Nyctanthes arbortristis for treating COVID-19.

导言:COVID-19 大流行是科学、医学和社会方面的一项重大挑战。由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的疾病进展的不可预测性突出表明,迫切需要确定针对病毒多个方面的化合物,以确保迅速有效的治疗。Nyctanthes arbortristis L.是一种娇嫩的多年生落叶灌木,遍布亚洲各个地区,其广泛的药理作用已得到认可,包括保肝、抗疟、抗菌、抗炎、抗氧化和抗病毒等特性:方法:各种体外研究揭示了 Nyctanthes arbortristis 对 COVID-19 的治疗意义。然而,确切的分子机制仍未阐明。在本研究中,我们采用了网络药理学方法来揭示旱金莲中治疗 COVID-19 的活性成分、潜在靶点和信号通路。在这一研究框架内,我们探索了有效成分-靶点-途径网络,发现柚皮酚、熊果酸、β-谷甾醇和白果甾醇通过影响IL6、MAPK3和MDM2基因,对COVID-19的发展起了决定性作用:结果:分子对接分析结果表明,Nyctanthes arbortristis在COVID-19中发挥了有效的结合能力。此外,我们还揭示了Nyctanthes arbortristis在COVID-19中的作用靶点、生物学功能和信号通路。分析表明,熊果苷可通过增强免疫功能、抑制炎症反应和调节细胞微环境来帮助治疗COVID-19。总之,本研究采用了一系列基于网络药理学和计算分析的方法来了解和表征连翘在COVID-19中的结合能力、生物功能、药理靶点和治疗机制:然而,这些研究结果并未在实际的COVID-19患者身上得到验证,因此还需要进一步的研究来确认旱莲草治疗COVID-19的潜在用途。
{"title":"An Integrative Network Pharmacology and Bioinformatics Approach for Deciphering the Multi-target Effect of Nyctanthes arbortristis L. against COVID-19.","authors":"Nagaraja Sreeharsha, Girish Meravanige Basavarajappa, Bandar Aloufi, Predeepkumar Narayanappa Shiroorkar, Md Khalid Anwer, Abdur Rehman","doi":"10.2174/0113816128298950240428013723","DOIUrl":"https://doi.org/10.2174/0113816128298950240428013723","url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 pandemic represents a significant challenge across scientific, medical, and societal dimensions. The unpredictability of the disease progression, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), underscores the urgent need for identifying compounds that target multiple aspects of the virus to ensure swift and effective treatment. Nyctanthes arbortristis L., a delicate, perennial, deciduous shrub found across various Asian regions, has been recognized for its wide range of pharmacological benefits, including hepatoprotective, antimalarial, antibacterial, anti-inflammatory, antioxidant, and antiviral properties.</p><p><strong>Methods: </strong>Various in vitro studies revealed the therapeutic significance of Nyctanthes arbortristis against COVID-19. However, the exact molecular mechanism remains unclarified. In the present study, a network pharmacology approach was employed to uncover the active ingredients, their potential targets, and signaling pathways in Nyctanthes arbortristis for the treatment of COVID-19. In the framework of this study, we explored the active ingredient-target-pathway network and figured out that naringetol, ursolic acid, betasitosterol, and daucosterol decisively contributed to the development of COVID-19 by affecting IL6, MAPK3, and MDM2 genes.</p><p><strong>Results: </strong>The results of molecular docking analysis indicated that Nyctanthes arbortristis exerted effective binding capacity in COVID-19. Further, we disclosed the targets, biological functions, and signaling pathways of Nyctanthes arbortristis in COVID-19. The analysis indicated that Nyctanthes arbortristis could help treat COVID-19 through the enhancement of immunologic functions, inhibition of inflammatory reactions and regulation of the cellular microenvironment. In short, the current study used a series of network pharmacologybased and computational analyses to understand and characterize the binding capacity, biological functions, pharmacological targets and therapeutic mechanisms of Nyctanthes arbortristis in COVID-19.</p><p><strong>Conclusion: </strong>However, the findings were not validated in actual COVID-19 patients, so further investigation is needed to confirm the potential use of Nyctanthes arbortristis for treating COVID-19.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current pharmaceutical design
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1